PMID- 36029887
OWN - NLM
STAT- MEDLINE
DCOM- 20221005
LR  - 20221005
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 191
DP  - 2022 Sep
TI  - Long-term influence of type 2 diabetes and metabolic syndrome on all-cause and 
      cardiovascular death, and microvascular and macrovascular complications in 
      Chinese adults - A 30-year follow-up of the Da Qing diabetes study.
PG  - 110048
LID - S0168-8227(22)00862-2 [pii]
LID - 10.1016/j.diabres.2022.110048 [doi]
AB  - AIMS: To examine the long-term influence of metabolic syndrome (MetS) on death 
      and vascular complications. METHODS: Altogether, 1419 individuals with different 
      levels of glycemia and MetS were recruited for this study. The participants were 
      followed up for 30 years to assess outcomes. RESULTS: Compared with the non_MetS, 
      individuals with impaired glucose tolerance (IGT) plus MetS had a higher 
      incidence (per 1000 person-years) of all-cause death (20.98 vs 11.70, hazard 
      ratio [HR] = 1.84), macrovascular events (29.25 vs 15.94, HR = 1.36), and 
      microvascular complications (10.66 vs 3.57, HR = 1.96). The incidence of these 
      outcomes was even higher in participants with type 2 diabetes mellitus (T2DM) 
      plus MetS. The T2DM without MetS shared a comparable risk profile of the outcomes 
      with the T2DM plus MetS group (HRs were 3.45 vs 3.15, 2.21 vs 2.65, and 6.91 vs 
      7.41, respectively). CONCLUSIONS: The degree of hyperglycemia in MetS is 
      associated with the severity of death and both micro- and macrovascular 
      complications. T2DM was associated with a comparable risk for all outcomes as 
      T2DM plus MetS. The findings highlight the need of early prevention of diabetes 
      in individuals with IGT plus MetS, while the justification to redefine a subgroup 
      of patients with T2DM as having MetS remains to be clarified.
CI  - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - He, Siyao
AU  - He S
AD  - Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing China.
FAU - Wang, Jinping
AU  - Wang J
AD  - Department of Cardiology, Da Qing First Hospital, Da Qing, China.
FAU - Zhang, Xiaoxing
AU  - Zhang X
AD  - Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing China.
FAU - Qian, Xin
AU  - Qian X
AD  - Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing China.
FAU - Yan, Shuang
AU  - Yan S
AD  - Department of Endocrinology, The Fourth Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Wang, Wenjuan
AU  - Wang W
AD  - Division of Non-Communicable Disease Control and Community Health, Chinese Center 
      for Disease Control and Prevention, Beijing, China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - China-Japan Friendship Hospital, Beijing, China.
FAU - Chen, Xiaoping
AU  - Chen X
AD  - China-Japan Friendship Hospital, Beijing, China.
FAU - An, Yali
AU  - An Y
AD  - Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing China.
FAU - Gong, Qiuhong
AU  - Gong Q
AD  - Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing China.
FAU - Zhang, Lihong
AU  - Zhang L
AD  - Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing China.
FAU - Zhu, Xiaolin
AU  - Zhu X
AD  - University of Alabama at Birmingham, Diabetes Research and Training Center, 
      Birmingham, AL 35233, USA.
FAU - Li, Hui
AU  - Li H
AD  - Department of Cardiology, Da Qing First Hospital, Da Qing, China.
FAU - Chen, Yanyan
AU  - Chen Y
AD  - Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing China.
FAU - Li, Guangwei
AU  - Li G
AD  - Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing China; China-Japan Friendship Hospital, 
      Beijing, China. Electronic address: guangwei_li45@126.com.
LA  - eng
PT  - Journal Article
DEP - 20220824
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
MH  - Adult
MH  - China/epidemiology
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Follow-Up Studies
MH  - *Glucose Intolerance/complications/epidemiology
MH  - Humans
MH  - *Metabolic Syndrome/complications/epidemiology
OTO - NOTNLM
OT  - Hyperglycaemia
OT  - Long-term
OT  - Macrovascular events
OT  - Metabolic syndrome
OT  - Microvascular complication
OT  - Type 2 diabetes
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/08/28 06:00
MHDA- 2022/10/06 06:00
CRDT- 2022/08/27 19:24
PHST- 2022/04/20 00:00 [received]
PHST- 2022/08/03 00:00 [revised]
PHST- 2022/08/19 00:00 [accepted]
PHST- 2022/08/28 06:00 [pubmed]
PHST- 2022/10/06 06:00 [medline]
PHST- 2022/08/27 19:24 [entrez]
AID - S0168-8227(22)00862-2 [pii]
AID - 10.1016/j.diabres.2022.110048 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2022 Sep;191:110048. doi: 10.1016/j.diabres.2022.110048. 
      Epub 2022 Aug 24.